Furman, Richard R.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 2,270

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 1,275

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 1,128

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood

Chronic Lymphocytic Leukemia ResearchT-cell and B-cell Immunology

Cited by 810

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 383

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Woyach, J. A., Smucker, K., Smith, L. L., Lozanski, A., Zhong, Y., Ruppert, A. S., Lucas, D., Williams, K., Zhao, W., Rassenti, L., et al. (2014) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 280

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

Gaiti, F., Chaligne, R., Gu, H., Brand, R. M., Kothen-Hill, S., Schulman, R. C., Grigorev, K., Risso, D., Kim, K.-T., Pastore, A., et al. (2019) · Nature

Chronic Lymphocytic Leukemia ResearchEpigenetics and DNA Methylation

Cited by 262

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentMultiple Myeloma Research and Treatments

Cited by 236

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., Robak, T., Kipps, T. J., Schuh, A., Moreno, C., et al. (2019) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 134

Activities of SYK and PLCγ2 Predict Apoptotic Response of CLL Cells to SRC Tyrosine Kinase Inhibitor Dasatinib

Song, Z., Lu, P., Furman, R. R., Leonard, J. P., Martin, P., Tyrell, L., Lee, F. Y., Knowles, D. M., Coleman, M., & Wang, Y. L. (2010) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 59